VOXZOGO POWDER AND DILUENT FOR INJECTION 0.56 MG [SIN17616P]
Active ingredients: VOSORITIDE
Product Info
VOXZOGO POWDER AND DILUENT FOR INJECTION 0.56 MG
[SIN17616P]
Product information
Active Ingredient and Strength | VOSORITIDE - 0.56 MG |
Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
Manufacturer and Country | VETTER PHARMA-FERTIGUNG GMBH & CO. KG (VOSORITIDE) - GERMANY |
Registration Number | SIN17616P |
Licence Holder | NOVEM HEALTHCARE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | M05BX07 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 THERAPEUTIC INDICATIONS
Voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Dosing
4.2 DOSE AND METHOD OF ADMINISTRATION
Treatment with Voxzogo should be initiated and directed by a physician appropriately qualified in the management of growth disorders or skeletal dysplasias.
Dosage
Voxzogo is given as a daily subcutaneous injection. The volume of Voxzogo to be administered at the recommended dose is based on the patient's weight and the vosoritide concentration (see Table 1). The dose can be administered using Unit (U) graduated syringes. The measurements for the Unit graduated syringes are equivalent to mL as follows: 0.1 mL = 10 Units. For practicality reasons and to account for weight-related PK changes (see section 5.2 Pharmacokinetic Properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information), the following dosing is recommended.

Duration of treatment
Treatment with Voxzogo should be stopped upon confirmation of no further growth potential, indicated by a growth velocity of <1.5 cm/year and closure of epiphyses.
Missed dose
If a dose of Voxzogo is missed, it can be administered within 12 hours. If more than 12 hours have passed since the original dosing schedule, the missed dose should NOT be administered. Patients/caregivers should be advised to continue with the next scheduled dose the following day.
Growth monitoring
Patients should be monitored and assessed regularly every 3–6 months to check body weight, growth and physical development. Dose should be adjusted according to the patient’s body weight (see Table 1).
Special populations
Patients with renal or hepatic impairment
The safety and efficacy of Voxzogo in patients with renal or hepatic impairment has not been evaluated.
Method of administration
Voxzogo is for subcutaneous single use in one patient only. Discard any residue. This medicinal product must be administered within 3 hours of reconstitution.
Prior to injecting, a healthcare professional should:
train caregivers on the preparation and subcutaneous injection of Voxzogo.
train caregivers and patients to recognise signs and symptoms of decreased blood pressure.
inform caregivers and patients what to do in the event of symptomatic decreases in blood pressure.
Patients and caregivers should be instructed to rotate sites for subcutaneous injections. Recommended injection sites on the body include the front middle of the thighs, the lower part of the abdomen except for 5 cm directly around the navel, top of the buttocks or the back of the upper arms. The same injection area should not be used on two consecutive days. Voxzogo should not be injected into sites that are red, swollen, or tender.
Patients should be well hydrated at the time of injection. It is recommended patients eat a light snack and drink an adequate amount of fluid (e.g., water, milk, juice, etc.) about 30 minutes before injecting. This is to reduce the signs and symptoms of potential decreases in blood pressure (dizziness, fatigue and/or nausea) occurring (see section 4.4, Blood pressure effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
If possible, Voxzogo should be injected at approximately the same time each day.
Preparation of Voxzogo for subcutaneous injection
The correct Voxzogo strength and correct pre-filled syringe of diluent (reconstitution volume) should be confirmed based on the patient’s body weight (see Table 1).
All necessary ancillary supplies must be in place before starting.
Alcohol pads
Gauze or bandages
Sharps container
The Voxzogo vial and diluent in a pre-filled syringe (water for injections) should be removed from the refrigerator and allowed to reach room temperature before reconstituting Voxzogo.
The diluent needle must be attached to the pre-filled syringe containing diluent (water for injections).
The entire diluent volume must be injected into the vial.
The diluent in the vial should be gently swirled until the white powder is completely dissolved. The vial should not be shaken.
The required dosing volume of the reconstituted solution should be slowly withdrawn from the single use vial into the administration syringe supplied (see Table 1). Only the administration syringe provided should be used for this step.
Once reconstituted Voxzogo is a clear, colourless to yellow liquid. The solution should not be used if discoloured or cloudy, or if particles are present.
After reconstitution, Voxzogo can be held in the vial at a room temperature up to 25 °C for a maximum of 3 hours. The medicinal product contains no preservative.
Each vial and pre-filled syringe are for single use only.
Contraindications
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
